glp-1 weight loss drug marketplace florida changes 2025 Antagonists Increase Plan Spend - What's Next Obesity GLP-1 Market Size to

Although GLP-1R expression in peripheral tissues is generally low and restricted to rare cell types (26), antiinflammatory benefits have been observed in various preclinical models, such as obesity, atherosclerosis, steatohepatitis, and nephritis, even in the absence of direct immune cell targeting (2732)

Samson SL, Vellanki P, Blonde L, et al

Based on the above pharmacological characteristics of categories of GLP-1RAs agents, despite slight adverse gastrointestinal side effects, it is clear that GLP-1RAs agents have efficacy in cardiovascular protection without untoward hypoglycemia

[DOI] [PubMed] [Google Scholar] 109.Kohut T.P.J

Beyond the cardiovascular effects of glucagon-like peptide-1 receptor agonists: body slimming and plaque stabilization

Abdelmalek, M